{'fraction_non_alphanumeric': 0.022988505747126436, 'fraction_numerical': 0.0, 'mean_word_length': 5.533333333333333, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Imatinib may reduce chemotherapy-induced pneumonitis. A report on four cases from the SWENOTECA

Abstract Background: An increasing number of anticancer drugs have been reported to cause pneumonitis. Chemotherapy-induced pneumonitis may cause severe morbidity and event death. As there has been a lack of effective treatment, new treatment strategies are needed. A previous case report has indicated that imatinib may be useful. Patient and methods: The SWENOTECA experience of four cases with severe life-threatening chemotherapy-induced pneumonitis treated with imatinib is presented. Results: All four patients responded to treatment with imatinib. Conclusions: Imatinib appears to be an effective treatment of severe chemotherapy-induced pneumonitis in germ cell cancer patients.